1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Drugs In Development, 2022, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 5, 1, 20 and 4 respectively.
Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Retinal Vein Occlusion - Overview
- Retinal Vein Occlusion - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Retinal Vein Occlusion - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Retinal Vein Occlusion - Companies Involved in Therapeutics Development
- Retinal Vein Occlusion - Drug Profiles
- Retinal Vein Occlusion - Dormant Projects
- Retinal Vein Occlusion - Discontinued Products
- Retinal Vein Occlusion - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Retinal Vein Occlusion, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Retinal Vein Occlusion - Dormant Projects, 2022
- Retinal Vein Occlusion - Discontinued Products, 2022
- Number of Products under Development for Retinal Vein Occlusion, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Allgenesis Biotherapeutics Inc
- ANBITION Srl
- Annexin Pharmaceuticals AB
- AsclepiX Therapeutics Inc
- AskGene Pharma Inc
- Avirmax Inc
- Calpain Therapeutics Pty Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Drive Therapeutics LLC
- EyePoint Pharmaceuticals Inc
- Eyevensys SAS
- F. Hoffmann-La Roche Ltd
- Kala Pharmaceuticals Inc
- Kiora Pharmaceuticals Inc
- Kodiak Sciences Inc
- Luye Pharma Group Ltd
- Novartis AG
- Novelty Nobility Inc
- Ocular Therapeutix Inc
- Outlook Therapeutics Inc
- Oxular Ltd
- Oxurion NV
- RevOpsis Therapeutics Corp
- Ripple therapeutics Corp
- Samsung Bioepis Co Ltd
- SIFI SpA
- Theratocular Biotek Co Ltd
- Uni-Bio Science Group Ltd
- Valitor Inc
